Working… Menu
Trial record 11 of 19 for:    lomitapide

Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04681170
Recruitment Status : Recruiting
First Posted : December 23, 2020
Last Update Posted : July 1, 2021
Information provided by (Responsible Party):
Amryt Pharma

Brief Summary:

This is a single arm, open label, multi centre phase III study to evaluate the efficacy and long term safety of lomitapide in paediatric patients with HoFH receiving stable LLT (including LA, when applicable) comprising of the following phases:

  • Screening Period (starting at Week 12, i.e. ≤12 weeks prior to Baseline for up to 6 weeks)
  • Stratified Enrolment and Start of Run in Period (starting at minimum at Week 6, i.e., 6 weeks prior to Baseline for a minimum of 6 weeks):
  • Efficacy Phase (starting at Baseline, i.e. Day [D] 0 for 24 weeks±3 days
  • Safety Phase (starting at Week 24±3 days for 80±1 weeks)

Condition or disease Intervention/treatment Phase
Homozygous Familial Hypercholesterolaemia (HoFH) Drug: Lomitapide Phase 3

Detailed Description:

Lomitapide has been approved for use in adult patients with HoFH in the European Union (EU) and European Economic Area (EEA), United States of America (USA), Israel, Argentina, Canada, Colombia, and Japan. This study is designed to determine if lomitapide is effective and can be safely administered to paediatric patients with HoFH. If the efficacy and safety so far observed in adults is confirmed in paediatric patients, the potential exists to significantly lower LDL C levels in paediatric patients with HoFH. Furthermore, the lower LDL C levels may reduce atherosclerosis progression and would be expected to benefit these paediatric patients with HoFH.

A single arm, non comparator design has been selected due to the rarity of the disease and because the evaluation of safety variables such as growth and sexual maturation requires longer term observation than would be feasible in the context of a placebo controlled study.

To mitigate the disadvantages of a single arm design, the study includes a Run in Period of at least 6 weeks during which current LLT (including LA, when applicable) will be stabilised to establish baseline levels allowing each patient to serve as his/her own control. Patients will also remain on stable LLT (including LA, when applicable) during the Efficacy Phase of the study through Week 24±3 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III, Single Arm, Open Label, International, Multi Centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid Lowering Therapy
Actual Study Start Date : November 23, 2020
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : September 30, 2023

Arm Intervention/treatment
Age 5-10 years
Age 5-10 years Lomitapide dosing will commence with 2mg at week 1 for 8 Weeks,then increase to 5mg Week 8±3 days, 10 mg at Week 12±3 days to the maximum allowable dose of 20 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
Drug: Lomitapide
2mg,5mg, 10mg and 20mg capsules

Lomitapide dosing will commence with 2mg at week 1 for 4 Weeks, then increase to 5mg Week 4±3 days, 10 mg at Week 8±3 days,20mgs at week, 12±3 days to the maximum allowable dose of 40 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
Drug: Lomitapide
2mg,5mg, 10mg and 20mg capsules

16 to ≤17 years
Lomitapide dosing will commence with 5mg at week 1 for 4 Weeks, then increase to 10mg Week 4±3 days,20 mg at Week 8±3 days,40mgs at week, 12±3 days to the maximum allowable dose of 60 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
Drug: Lomitapide
2mg,5mg, 10mg and 20mg capsules

Primary Outcome Measures :
  1. Efficacy endpoint Percent change in LDL C [ Time Frame: Baseline through Week 104±1 week ]
    To evaluate the efficacy of lomitapide, as defined by the percent change in low density lipoprotein cholesterol (LDL C) at the maximum tolerated dose (MTD)

  2. Safety endpoints AE reporting [ Time Frame: Baseline through Week 104±1 week ]
    Incidence, severity, and relatedness of AEs

Secondary Outcome Measures :
  1. Percent change from Baseline at Week 24±3 days for the following lipid parameters: TC, Non HDL C, VLDL C, TG, Lp(a), and apoB [ Time Frame: Baseline through Week 104±1 week ]
  2. Percent change from Baseline at all other time points through Week 104±1 week for the following lipid parameters: LDL C, TC, Non HDL C, VLDL C, TG, Lp(a), and apo B [ Time Frame: Baseline through Week 104±1 week ]
  3. • Change in LLT and LA from Week 24±3 days through Week 104±1 week [ Time Frame: Baseline through Week 104±1 week ]
  4. • Total number and percent of patients achieving the EAS recommended target LDL C of <135 mg/dL (3.5 mmol/L) in paediatric HoFH patients at Week 24±3 days and at any time on study [ Time Frame: Baseline through Week 104±1 week ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Male and female patients aged 5 to ≤17 years with HoFH as defined by any of the following criteria recommended by the Consensus Panel on Familial Hypercholesterolaemia of the EAS (Cuchel, Bruckert et al. 2014):

    1. Genetic confirmation of 2 mutant alleles at the LDL receptor (LDLR), apo B, Proprotein convertase subtilisin/kexin type 9 (PCSK9), or LDL receptor adapter protein 1 (LDLRAP1) gene locus OR
    2. An untreated LDL C >500 mg/dL (13 mmol/L) or treated LDL C ≥300 mg/dL (8 mmol/L ) together with either Cutaneous or tendon xanthoma before age 10 years or Untreated LDL C levels consistent with heterozygous FH in both parents
  • Baseline LDL C on LLT (maximum concentration [Cmax] immediately prior to LA, if applicable)

    1. >160 mg/dL (4.1 mmol/L, no documented cardiovascular disease [CVD]) or
    2. >130 mg/dL (3.4 mmol/L, established CVD defined as aortic valve disease and/or coronary atherosclerosis)
  • Body weight ≥15 kg or BMI and height both >10th percentile according to World Health Organization (WHO) Growth Charts for Boys and Girls 5 to 19 Years of Age
  • Patient and/or his/her legal representative has/have been informed, has/have read and understood the patient information/informed consent form, and has/have given written informed assent/consent
  • Patient and/or his/her legal representative must be able and willing to follow study procedures and instructions, particularly that

    1. LLT (including LA, when applicable) must be stable for at least 6 weeks prior to Baseline (Run in Period) and remain stable through Week 24±3 days (end of Efficacy Phase)
    2. The patient must be compliant with both the low fat diet supplying <20% of energy (calories) from fat or <30 g fat, whichever is the lesser amount starting at the beginning of the Run in Period and the dietary supplement regimen starting at Week 2 of the Run in Period, both continuing until completion of the study
  • Postmenarchal female adolescents must be willing to use an effective form of birth control with failure rates <1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomy or vasectomised partner) during participation in the study (and at least 4 weeks thereafter). Patients taking oestrogen based oral contraceptives should be advised about possible loss of effectiveness due to diarrhea and/or vomiting. Additional contraceptive measures should be used for 7 days after resolution of symptoms.
  • Patient must be in stable physical and mental health at screening

Exclusion criteria

  • Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g., nephrotic syndrome, hypothyroidism)
  • Contraindications for the use of lomitapide according to section 4.3 of the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC), such as hypersensitivity to the active substance or to any of the excipients listed in Section 6.1 of the SmPC, known significant or chronic inflammatory bowel disease or malabsorption
  • Moderate (Child Pugh B) or severe hepatic impairment (Child Pugh C), active liver disease and/or abnormal liver function tests at screening (AST or ALT >1.5 x upper limit of normal (ULN) and/or total bilirubin >1.5 x ULN in the absence of Gilbert's syndrome or AP >1.5 x ULN [based on appropriate age and gender normal values])
  • Serum CK >2 x ULN
  • Chronic renal insufficiency with glomerular filtration rate (GFR) <70 mL/min/1.73 m2 calculated using the Schwartz formula
  • Uncontrolled hypertension (defined as mean systolic and/or diastolic blood pressure ≥95% of normal for age and sex) despite medical therapy
  • New York Heart Association (NYHA) Class III or IV congestive heart failure
  • Precocious/delayed puberty or endocrine disorder affecting growth (e.g., hypothyroidism, premature adrenarche)
  • History of drug abuse within the last 3 years or habitual alcohol consumption (defined as >1 ounce [28 g] of liquor or 4 ounce glass [113 g] of wine, or the equivalent, ≥3 times per week)
  • Life expectancy predicted to be <5 years
  • History of a non skin malignancy (with the exception of cervical cancer in situ) within 3 years prior to enrolment
  • Treatment with any Investigational Medicinal Product (IMP) within 6 months or 5 times the terminal half life of the corresponding IMP, whichever is longer, before the screening visit
  • Patient is a dependent of the sponsor, of the investigational team or his/her immediate family
  • Pregnant or nursing women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04681170

Layout table for location contacts
Contact: Ruth Nallen +35315180200
Contact: Medical Monitor +35315180200

Layout table for location information
Universtiats-Kinderlinik Heidelberg Recruiting
Heidelberg, Baden-Wurttemberg, Germany, 69120
Contact: Claus P Schmitt, MD         
Principal Investigator: Claus P Schmitt, MD         
University Hospital of Cologne Not yet recruiting
Cologne, Germany, 50937
Contact: Christina Taylan, MD         
Principal Investigator: Christina Taylan, MD         
University Medical Center Hamburg-Eppendorf Recruiting
Hamburg, Germany, 20246
Contact: Jun OH, MD         
Principal Investigator: Jun OH, MD         
Rambam Medical Center Recruiting
Haifa, Israel, 31096
Contact: Prof R Shaoul         
Chaim Sheba Medical Center Recruiting
Ramat Gan,, Israel, 52621
Contact: Dr H Cohen         
U.O.C. Clinica Medica 1 Recruiting
Padova, Padua, Italy, 35128
Contact: Alberto Zambon, Prof         
A.O.R.N. "Sant' Anna e San Sebastiano" di Caserta Recruiting
Caserta, Italy, 81100
Contact: Paolo Calabreò, MD         
Bambino Gesù Children's Hospital, Recruiting
Roma, Italy, 00165
Contact: Dr S Buonuomo         
Saudi Arabia
King Abdullah International Medical Research Centre (KAIMRC), Not yet recruiting
Riyadh, Saudi Arabia
Contact: Dr M Al-Dubayee, MD         
Hospital Universitari Sant Joan Recruiting
Reus, Tarragona,, Spain, 43204
Contact: Prof Luis Masana Martin         
Hospital Abente y Lago Recruiting
A Coruña, Spain, 15006
Contact: Dr Jose L Diaz-Diaz         
Hospital Clinico Universitario of Valencia Recruiting
Valencia, Spain, 46010
Contact: Dr Sergio Martinez         
E.P.S. Fattouma Bourguiba Hospital Recruiting
Monastir,, Tunisia, 5000
Contact: Dr F Maatouk         
Sponsors and Collaborators
Amryt Pharma
Layout table for additonal information
Responsible Party: Amryt Pharma Identifier: NCT04681170    
Other Study ID Numbers: APH-19
First Posted: December 23, 2020    Key Record Dates
Last Update Posted: July 1, 2021
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperlipoproteinemia Type II
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn